In addition, p110δ has also emerged as a key therapeutic target for haematological malignancies [14,15], notably acute myeloid leukaemia (AML), and there is also some evidence that this isoform is upregulated in melanoma and breast cancer, and is overexpressed in neuroblastoma [4]. The gene discussed is PIK3CD; the disease is breast cancer.